The conversation discusses a new hair growth treatment that showed a 14 hairs/cm2 increase in a trial, with mixed opinions on its effectiveness and potential cost. Some users are hopeful about combining it with existing treatments like oral minoxidil for better results.
A user is considering starting finasteride for hair thinning but is concerned about side effects like low libido and gynecomastia. They plan to consult a dermatologist and are advised to test DHT, testosterone, and estradiol levels.
A user shared their successful hair regrowth journey using finasteride, oral minoxidil, and oral dutasteride, expressing gratitude for the support received. The conversation includes congratulations and encouragement from others.
The conversation discusses using topical synthetic prostaglandins like Bimatoprost, Latanoprost, and cetirizine for hair growth. The user shares a link suggesting these treatments may be effective.
The user is using a hair loss treatment involving dutasteride, minoxidil, finasteride, microneedling, and supplements like multivitamins, D3 K2, and Omega 3 fish oil. They are considering adding tretinoin and are open to suggestions while managing gut issues.
Kintor Pharma completed a successful Phase II clinical trial for KX-826, a treatment for androgenetic alopecia. KX-826 is similar to finasteride with minor side effects and is more backed than Cosmerna.
The user underwent a second hair transplant for the crown and mid-scalp, achieving good density. They are using minoxidil, finasteride, and biotin, and considering PRP treatments to enhance growth.
The user plans to pause finasteride for two months to test its effects on mood and productivity, then switch to Pyrilutamide while monitoring hormone levels. Concerns are raised about potential hair loss and the effectiveness of Pyrilutamide compared to finasteride.
The user is experiencing increased hair shedding after one year of using oral dutasteride. They are seeking opinions on their DHT test results, which show levels below baseline.
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
The user has been experiencing diffuse hair thinning despite using finasteride, minoxidil, dermarolling, clobetasol cream, and PRP sessions. They seek advice on additional treatments and are advised to check vitamin D, iron, and thyroid levels.
Hair loss discussion involves minoxidil, finasteride, and RU58841. Minoxidil non-responders may see results after adding stemoxydine due to increased enzyme presence.
A user shared their hair regrowth progress using Dutasteride, topical Minoxidil, Spironolactone, and Estradiol Valerate injections as part of hormone replacement therapy for transitioning. They experienced significant hair improvement and personal satisfaction but caution against this approach for non-transitioning individuals due to irreversible changes.
The user experienced erectile dysfunction from oral finasteride and is considering alternatives like topical high-dose finasteride, RU58841, topical Latanoprost, and oral Minoxidil. Blood tests showed changes in testosterone and DHT levels, and the endocrinologist advised stopping finasteride.
Finasteride may have positive effects by keeping testosterone levels higher, potentially maintaining youthfulness and physical performance as one ages. It could also help with conditions related to aging like andropause and sarcopenia without increasing estradiol levels.
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
The conversation discusses the impact of finasteride on sperm, including potential side effects like decreased ejaculate volume and total sperm count. Users share experiences and concerns about fertility tests before and after starting finasteride.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
A 32-year-old male started taking 0.5mg of finasteride daily for hair thinning and, after 8 weeks, experienced a 70% reduction in DHT and an increase in estradiol; he is currently in the shedding phase of treatment and questioning if the dosage is correct based on his DHT levels. He began with a lower dose due to already low normal testosterone and DHT levels.
A user was prescribed betamethasone dipropionate spray for a receding hairline, which caused skin peeling and depigmentation. They stopped using it and are considering alternatives like BPC-157/TB-500 for healing.
The user is considering switching to oral dutasteride, topical minoxidil, retinoic acid, and clobetasol for hair loss treatment, after limited regrowth with finasteride and other topicals. They are seeking a source for clobetasol, as they believe it may help with their condition.
Finasteride can increase total testosterone and potentially raise estrogen levels, leading to side effects. Biotin in combined tablets can falsely elevate thyroid hormone levels in blood tests.
Progesterone, hydrocortisone butyrate, and estrone base are discussed as treatments for hair loss. Topical progesterone and dutasteride are suggested to potentially reverse androgenic alopecia.
Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.
An 18-year-old is considering testosterone replacement therapy with finasteride or dutasteride for hair loss but worries about side effects. Users recommend alternatives like minoxidil, RU58841, and consulting a doctor.
The user is experimenting with GHK-Cu and AHK-Cu to stop hair loss and promote hair growth, using a serum from Etsy and injectable GHK-Cu. They supplement this with dermastamping and ketoconazole shampoo.
The conversation is about managing hair loss while on hormone replacement therapy (HRT) with estrogen and spironolactone. The user considers adding finasteride but decides to wait and see the effects of the current treatment.
A user preparing to start finasteride for hair loss wanted to check for any abnormal bloodwork related to hair loss. They shared their blood test results and learned from another user that their doctor prescribed finasteride without any preliminary tests.